文献速递免疫规划妇幼与学校卫生

原型重组α样蛋白亚单位疫苗GBS-NN在健康成年女性中的安全性与免疫原性:随机安慰剂对照双盲1期试验

Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women.
PubMed 文献 · Vaccine · 2021-06-30

本研究在健康非孕女性中评估GBS-NN疫苗的安全性与免疫原性。剂量递增阶段测试10、50、250 µg含或不含氢氧化铝佐剂(n=60),随后剂量确认阶段比较100 µg佐剂单剂与50或100 µg佐剂两剂(n=180)。疫苗耐受良好,佐剂显著提高抗体浓度,两剂50 µg方案免疫原性最佳。

要点

  • GBS-NN疫苗耐受良好,主要为轻度注射部位反应。
  • 佐剂显著提高抗体浓度,第二剂可增强免疫应答。
  • 两剂50 µg佐剂方案免疫原性最佳,IgG GMC达16.9 µg/ml。

核心结论

  • 原型GBS-NN疫苗耐受良好且高度免疫原性,最佳方案为两剂50 µg加佐剂。
  • 基于GBS α样蛋白家族N端结构域的母体疫苗值得进一步开发。

研究设计与样本

  • 随机、双盲、安慰剂对照、平行组1期研究,在健康非孕女性中进行。
  • 剂量递增阶段:两剂(间隔4周)10、50或250 µg含或不含氢氧化铝佐剂(n=60)。
  • 剂量确认阶段:100 µg佐剂单剂与50或100 µg佐剂两剂(间隔4周)比较(n=180)。
  • 安全性和免疫原性监测1年。

主要发现

  • GBS-NN耐受良好,观察到一些主要为轻度的注射部位反应。
  • 佐剂显著增加抗体浓度,第二剂可增强应答。
  • 整个1年研究期间IgG GMC保持强烈升高。
  • 该方案下,100%和89%的受试者分别达到高于1 µg/ml和4 µg/ml任意阈值的抗体水平。

关键数值与推荐

  • 该方案下100%受试者抗体水平>1 µg/ml,89%>4 µg/ml。

临床怎么用

  • 支持进一步开发基于GBS α样蛋白家族N端结构域的母体疫苗。
  • 最佳候选方案为两剂50 µg加佐剂,间隔4周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Group B Streptococcus (GBS) is the leading cause of life-threatening infections in new-borns and may cause invasive disease, stillbirth and preterm delivery during pregnancy. While no licensed vaccine exists, maternal immunization might protect against neonatal disease and adverse pregnancy outcomes. We assessed the safety and immunogenicity of a prototype vaccine consisting of the fused N-terminal domains of the AlphaC and Rib surface proteins of GBS (GBS-NN). METHODS: GBS-NN was tested in a randomised, double-blind, placebo-controlled, parallel group, phase I study, in healthy non-pregnant women. A dose-escalation phase, with two doses, four weeks apart, of 10, 50 or 250 µg, administered with or without aluminium hydroxide, was initially assessed (n = 60). This was followed by a dose-confirmation study, where one dose of 100 µg adjuvanted GBS-NN was compared with two doses of either 50 or 100 µg adjuvanted GBS-NN, again administered with four weeks interval between the doses (n = 180). Safety and immunogenicity were monitored for one year. RESULTS: GBS-NN was well tolerated with some, mostly mild, injection site reactions observed. Adjuvant significantly increased antibody concentrations and the response was boosted by a second dose. The IgG GMCs remained strongly elevated during the whole one-year duration of the study. Maximal responses occurred after two 50 µg doses, resulting in IgG GMC of 16.9 µg/ml at the primary immunological endpoint, twelve weeks after the first dose. For this regimen, 100% and 89% of the subjects achieved antibody levels above the arbitrary thresholds of 1 and 4 µg/ml, respectively. The added beneficial effect of a second dose was most pronounced for subjects with pre-existing IgG levels below the median of the entire cohort. CONCLUSION: The prototype GBS-NN vaccine was found to be well tolerated and highly immunogenic with an optimal regimen of two doses of 50 µg in the presence of adjuvant. Further development of a maternal vaccine based on the N-terminal domains of the alpha-like protein family of GBS is warranted (NCT02459262).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fischer P, Pawlowski A, Cao D, et al. Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women. Vaccine. 2021. PMID: 34215454. doi:10.1016/j.vaccine.2021.06.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。